Evidence map›Paper›PMID 36913352›Full record

ArticlePloS one2023

Is there a "price that's right" for at-home COVID tests?

Rebecca Portney Kirby, Michal Maimaran, Kara M Palamountain

Full text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rebecca Portney KirbyKellogg School of Management, Northwestern University, Evanston, Illinois, United States of America.ORCID 0000-0001-8724-7871
Michal MaimaranKellogg School of Management, Northwestern University, Evanston, Illinois, United States of America.
Kara M PalamountainKellogg School of Management, Northwestern University, Evanston, Illinois, United States of America.

Funding

The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep DiseasesU54HL143541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BRYAN O BUCHHOLZ, Nathaniel Scott Hafer · 2018 to 2026
$141.0M
The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental RequestU54EB027049 · NIBIB · NORTHWESTERN UNIVERSITY · PI Chad J Achenbach, SALLY Maureen MCFALL · 2018 to 2026
$24.0M
NHLBI NIH HHS U54 HL143541NIBIB NIH HHS U54 EB027049
6 · The paper itself

Abstract

The COVID-19 pandemic has impacted the daily lives of individuals across the world as multiple variants continue introducing new complexities. In December 2021, which is when we conducted our study, pressure to resume the normalcy of daily life was mounting as a new variant, Omicron, was rapidly spreading. A variety of at-home tests detecting SARS-CoV-2, known to the general public as "COVID tests," were available for consumers to purchase. In this study, we conducted conjoint analysis utilizing an internet-based survey by presenting consumers (n = 583) with 12 different hypothetical at-home COVID test concepts that varied on five attributes (price, accuracy, time, where-to-buy, and method). Price was identified as the most important attribute, because participants were very price sensitive. Quick turnaround time and high accuracy were also identified as important. Additionally, although 64% of respondents were willing to take an at-home COVID test, only 22% reported they had previously taken the test. On December 21, 2021, President Biden announced the U.S. government would purchase 500 million at-home rapid tests and distribute them for free to Americans. Given the importance of price to participants, this policy of providing free at-home COVID tests was directionally appropriate.

Indexed as

COVID-19Consumer BehaviorHumansPandemicsSARS-CoV-2Surveys and QuestionnairesUnited States

Identifiers

PMID36913352
PMCPMC10010528

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read132
identifiers read6
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.